For the quarter ending 2026-03-31, OPRX had -$3,196K decrease in cash & cash equivalents over the period. -$488K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Goodwill impairment | - | - | 0 | - |
| Impairment charges | - | 368 | - | - |
| Bad debt expense | - | 0 | 0 | 0 |
| Net loss | -495 | 5,020 | 779 | -667 |
| Depreciation and amortization | 1,064 | 1,078 | 1,081 | 2,168 |
| Stock-based compensation | 1,828 | 1,960 | 1,956 | 3,046 |
| Amortization of debt issuance costs | 358 | 325 | 174 | 611 |
| Accounts receivable | -5,763 | 5,525 | -1,285 | -4,700 |
| Prepaid expenses and other assets | 290 | 19 | -510 | 958 |
| Accounts payable | 1,430 | -401 | 55 | -174 |
| Revenue share payable | -2,131 | 757 | -262 | -2,462 |
| Accrued expenses and other liabilities | -7,989 | 1,461 | -2,225 | 4,138 |
| Operating lease liabilities | -2 | -3 | 6 | 9 |
| Taxes receivable and payable | -119 | 995 | -1,101 | -964 |
| Deferred tax liabilities, net | 50 | -1,214 | -1,033 | 1,033 |
| Deferred loan fees | - | 250 | - | - |
| Deferred revenue | 166 | 108 | -89 | 11 |
| Net cash (used in) provided by operating activities | -467 | 7,088 | 3,202 | 8,425 |
| Purchases of property and equipment | 21 | 11 | 10 | 37 |
| Capitalized software development costs | 0 | 35 | 0 | 91 |
| Net cash used in investing activities | -21 | 206 | -10 | -128 |
| Cash paid for employee withholding taxes related to the vesting of restricted stock units | - | 962 | 188 | - |
| Proceeds from exercise of stock options, net of cash paid for withholding taxes | - | 14 | 338 | - |
| Cash paid for employee withholding taxes related to the vesting of restricted stock units | -75 | - | - | 92 |
| Repayment of long-term debt | 2,691 | 2,500 | 500 | 5,000 |
| Net cash used in financing activities | -2,708 | -3,448 | -258 | -5,092 |
| Net (decrease) increase in cash and cash equivalents | -3,196 | 3,846 | 2,934 | 3,205 |
| Cash and cash equivalents - beginning of period | 23,365 | 19,519 | 13,380 | - |
| Cash and cash equivalents - end of period | 20,169 | 23,365 | 19,519 | - |
OptimizeRx Corp (OPRX)
OptimizeRx Corp (OPRX)